生物科技指数ETF-iShares Nasdaq(IBB)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

IBB 生物科技指数ETF-iShares Nasdaq

盘前交易 10-02 08:54:00 EDT

205.96

-4.57

-2.17%

盘前207.80

+1.84+0.89%

08:50 EDT

最高211.73	最低205.84	成交量154.69万
今开210.09	昨收210.53	日振幅2.80%
总市值104.52亿	流通市值104.52亿	总股本5,075万
成交额3.22亿	换手率3.05%	流通股本5,075万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"IBB","market":"US","secType":"STK","nameCN":"生物科技指数ETF-iShares Nasdaq","latestPrice":205.96,"timestamp":1790884800000,"preClose":210.53,"halted":0,"volume":1546879,"hourTrading":{"tag":"盘前","latestPrice":207.8,"preClose":205.96,"latestTime":"08:50 EDT","volume":1311,"amount":271619.88897,"timestamp":1790945442466,"change":1.84,"changeRate":0.008934,"amplitude":0.020392},"delay":0,"changeRate":-0.021707120125397772,"floatShares":50750000,"shares":50750000,"eps":6.311863,"marketStatus":"盘前交易","change":-4.57,"latestTime":"10-02 08:54:00 EDT","open":210.085,"high":211.73,"low":205.84,"amount":321610885.85687,"amplitude":0.027977,"askPrice":212.26,"askSize":100,"bidPrice":206.38,"bidSize":10,"shortable":3,"etf":1,"ttmEps":6.311863,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1790947800000},"marketStatusCode":1,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":205.96,"sharesOutstanding":50050000,"nav":210.463323,"aum":11112463454.4,"dividendRate":0.001637,"bidAskSpread":0.00039,"preHourTrading":{"tag":"盘前","latestPrice":207.8,"preClose":205.96,"latestTime":"08:50 EDT","volume":1311,"amount":271619.88897,"timestamp":1790945442466,"change":1.84,"changeRate":0.008934,"amplitude":0.020392},"postHourTrading":{"tag":"盘后","latestPrice":205.96,"preClose":205.96,"latestTime":"19:30 EDT","volume":7162,"amount":1475288.405,"timestamp":1790897406045,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.0667695497710206,"impliedVol":0.2407,"impliedVolPercentile":0.6},"requestUrl":"/m/hq/s/IBB","defaultTab":"news","newsList":[{"id":"2672753398","title":"三星生物制药与梯瓦制药扩大战略合作，推进至多六款候选生物类似药研发.","url":"https://stock-news.laohu8.com/highlight/detail?id=2672753398","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2672753398?lang=zh_cn&edition=full","pubTime":"2026-10-01 16:30","pubTimestamp":1790843422,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU2324357040.USD","MRNX","BK4584","EMXC","LU1992135399.USD","PPH","BK4559","XPH","TEVA","BK4596","MRNY","BK4557","BK4588","LU2322448957.HKD","BBP","BK4585","IE00B5TLWC47.USD","LU2322448791.USD","BK4007","LU2272731600.USD","LU1983299246.USD","LU2473716301.USD","IBBQ","BK4566","LU1992135472.HKD","LU2272731782.SGD","LU2272731865.HKD","IBB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671800297","title":"花旗：中国生物制药(01177)与STADA达成生物类似药战略合作 维持“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2671800297","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671800297?lang=zh_cn&edition=full","pubTime":"2026-09-29 16:42","pubTimestamp":1790671365,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，花旗发布研报称，中国生物制药旗下正大天晴与德国药企STADA就生物类似药达成战略合作，授予STADA在欧盟、瑞士、英国及独立国家联合体商业化帕博利珠单抗生物类似药的独家许可，并可选择拓展至美国及海湾合作委员会成员国市场。中生制药透露年内对外授权交易合计首付款及近期里程碑付款达3.55亿美元，潜在总交易金额达34亿美元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1502057.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01177","PPH","XPH","IBB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670233174","title":"正大天晴与STADA达成生物类似药战略合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2670233174","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670233174?lang=zh_cn&edition=full","pubTime":"2026-09-28 17:33","pubTimestamp":1790587999,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IBB","LU1992135472.HKD","LU2272731600.USD","LU2322448791.USD","LU2473716301.USD","LU2272731865.HKD","PPH","BK4585","LU2322448957.HKD","LU2272731782.SGD","XPH","IE00B5TLWC47.USD","BK4588","LU1992135399.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670023840","title":"罗氏：公司整理的分析师共识显示，预计到2030年生物类似药将造成62亿瑞士法郎的销售缺口。","url":"https://stock-news.laohu8.com/highlight/detail?id=2670023840","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670023840?lang=zh_cn&edition=full","pubTime":"2026-09-28 17:07","pubTimestamp":1790586449,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU2272731600.USD","PPH","LU1992135472.HKD","BK4585","LU1992135399.USD","LU2322448957.HKD","XPH","BK4588","LU2322448791.USD","LU2473716301.USD","IE00B5TLWC47.USD","IBB","LU2272731782.SGD","LU2272731865.HKD","FXF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670387092","title":"中国生物制药：附属公司与STADA达成生物类似药合作，最高可获里程碑款5300万欧元","url":"https://stock-news.laohu8.com/highlight/detail?id=2670387092","media":"财中社","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670387092?lang=zh_cn&edition=full","pubTime":"2026-09-28 16:57","pubTimestamp":1790585820,"startTime":"0","endTime":"0","summary":"9月28日，中国生物制药（01177）发布公告，附属公司正大天晴药业集团股份有限公司与STADAArzneimittelAG已就生物类似药达成战略合作，双方将携手提升生物类似药在全球多个地区的患者可及性。根据协议的条款及条件，正大天晴将获得首付款，并有权获得潜在开发、监管及销售里程碑付款，合计最高可达5300万欧元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609283885246557.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609283885246557.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["IBB","LU1992135472.HKD","IE00BZ08YR35.GBP","FXE","LU2272731865.HKD","LU2272731600.USD","LU2272731782.SGD","HK0000165453.HKD","IE00BZ08YS42.EUR","BK1515","BK4585","BK1589","LU2322448957.HKD","LU2473716301.USD","LU1992135399.USD","IE00B5TLWC47.USD","NBIE","PPH","IE00BZ08YT58.USD","BK4588","XPH","BK1191","LU2322448791.USD","BK1521","01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669453169","title":"安进一种自身免疫药物在后期临床试验达到主要目标","url":"https://stock-news.laohu8.com/highlight/detail?id=2669453169","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669453169?lang=zh_cn&edition=full","pubTime":"2026-09-24 10:32","pubTimestamp":1790217159,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU2242646821.SGD","IE0009355771.USD","IE00B2B36J28.USD","LU0058720904.USD","MDTX","IE00BFTCPJ56.SGD","BBH","LU0109394709.USD","LU0868494617.USD","BK4566","IBBJ","LU0122379950.USD","LU1057294990.SGD","LU0889565916.HKD","BK4599","BK4534","LU2112291526.USD","BK4588","IE0002141913.USD","IE00BJJMRZ35.SGD","PJP","PBE","IBB","SG9999001440.SGD","BK4585","LU1983299246.USD","BK4139","BK4533","TBXU","IBBQ","LU0289739699.SGD","PSYK","IE00BJT1NW94.SGD","IE00B4R5TH58.HKD","AMGN","BMED","LU1571399168.USD","BK4581","LU2468319806.SGD","LU0320765992.SGD","LU1023059063.AUD","BIB","LU2089984988.USD","LU2242652126.USD","LU1061106388.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121969920","title":"安进宣布Dazodalibep在干燥综合征III期试验中达到主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=1121969920","media":"投资观察","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1121969920?lang=zh_cn&edition=full","pubTime":"2026-09-22 21:50","pubTimestamp":1790085037,"startTime":"0","endTime":"0","summary":"路透社9月22日消息——安进公司（Amgen Inc）于近日披露其关键临床进展：\n安进旗下药物Dazodalibep在针对中重度症状性干燥综合征的III期OASIZ 303研究中，成功达到主要终点，该项试验预计将于2026年第四季度完成。\n安进表示，Dazodalibep在III期干燥综合征试验中取得主要终点的积极结果，该药物在系统性疾活动度方面展现出具有统计学显著性及临床意义的改善。\n值得注意的是，这一进展为干燥综合征患者群体带来了新的治疗希望。安进公司股票代码为AMGN.O。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4566","PJP","IE00BJJMRZ35.SGD","IE00BJT1NW94.SGD","BK4581","IBBQ","BK4534","IE0002141913.USD","PBE","LU0109394709.USD","BIB","BBH","LU2089984988.USD","IBB","LU1061106388.HKD","IE00BFTCPJ56.SGD","IE00B2B36J28.USD","BK4588","LU0320765992.SGD","LU1571399168.USD","LU2468319806.SGD","IE0009355771.USD","SG9999001440.SGD","LU2242646821.SGD","BK4599","LU0122379950.USD","LU0868494617.USD","LU0289739699.SGD","LU1057294990.SGD","IE00B4R5TH58.HKD","BK4533","BK4585","LU2112291526.USD","LU2242652126.USD","LU1983299246.USD","AMGN","LU1023059063.AUD","TBXU","LU0889565916.HKD","BK4139","LU0058720904.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669114208","title":"安进股价盘前大涨逾4%，受第三期临床试验结果提振。","url":"https://stock-news.laohu8.com/highlight/detail?id=2669114208","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669114208?lang=zh_cn&edition=full","pubTime":"2026-09-22 21:07","pubTimestamp":1790082475,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU0109394709.USD","MRNY","BME","PBPH","LFSC","BBH","IBBQ","HELX","IYH","LU0122379950.USD","LU2242646821.SGD","IBRN","PBE","PSCH","SBIO","BBP","XPH","SYNB","IBB","RXL","TBXU","LU2473716301.USD","LU0320765992.SGD","MEDI","BK4585","FTXH","LU0058720904.USD","GNOM","FBT","IE00B5TLWC47.USD","XBIX","PJP","BK4599","BIB","LU2272731782.SGD","WDNA","MRNX","RSPH","IEIH","LU2272731865.HKD","PPH","AZNH","IE00B4R5TH58.HKD","AMGN","IEHS","LU1992135472.HKD","IDNA","TMED","CANC","BIOY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198157419","title":"福泰制药宣布Inaxaplin在特定AMKD患者群体中取得积极结果，第13周UACR显著降低42.7%","url":"https://stock-news.laohu8.com/highlight/detail?id=1198157419","media":"投资观察","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1198157419?lang=zh_cn&edition=full","pubTime":"2026-09-22 21:06","pubTimestamp":1790082369,"startTime":"0","endTime":"0","summary":"路透社9月22日消息——福泰制药 今日发布重大公告，披露其在APOL1介导肾病额外患者群体中开展的2b期AMPLIFIED研究取得积极成果。详细数据显示，对于伴有中度蛋白尿的AMKD患者，Inaxaplin在治疗第13周时使尿白蛋白肌酐比较基线下降了42.7%。两项研究队列均显示，Inaxaplin总体安全性和耐受性良好，未出现意外安全信号。值得注意的是，这是福泰制药在这两个特定亚群中首次公布Inaxaplin的临床数据，进一步拓展了该药物在AMKD治疗领域的潜在应用范围。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2237438978.USD","LU2468319806.SGD","LU1069344957.HKD","GNMX","VRTX","IE00B19Z9Z06.USD","LU0432979614.USD","IE00B894F039.SGD","LU1778281490.HKD","SG9999013999.USD","IE00B19Z9P08.USD","IE0002270589.USD","IE00B19Z3B42.SGD","LU2456880835.USD","IBBQ","IE0009355771.USD","LU1430594728.SGD","LU1585245621.USD","LU0061475181.USD","PBE","IE00BJT1NW94.SGD","LU2462157665.USD","IBB","LU0823416689.USD","IE00BJJMRZ35.SGD","LU0079474960.USD","LU2236285917.USD","BK4533","SG9999001176.SGD","LU0109394709.USD","BK4139","BK4585","BK4532","LU0234570918.USD","LU2089984988.USD","BK4567","LU0320765992.SGD","SG9999001176.USD","LU0058720904.USD","LU2417539215.USD","IDNA","LU1674673428.USD","LU0889565916.HKD","IE00B19Z3581.USD","IE00B2B36J28.USD","LU2362541513.USD","LU1674673691.USD","LU2324357040.USD","LU1093756325.SGD","LU2362541273.HKD","IE00BFTCPJ56.SGD","LU1035775433.USD","LU0417517546.SGD","IE00B4R5TH58.HKD","IE00BZ9MQY76.HKD","LU2362540622.SGD","BK4588","SGXZ57979304.SGD","LU0256863811.USD","LU0289739699.SGD","BIB","TBXU","BBH","LU1093756168.USD","IE0002141913.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167058424","title":"安进宣布Dazodalibep治疗中重度系统性干燥综合征的3期临床试验取得积极顶线结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1167058424","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1167058424?lang=zh_cn&edition=full","pubTime":"2026-09-22 21:04","pubTimestamp":1790082253,"startTime":"0","endTime":"0","summary":"安进公司今日发布重磅消息：其研发的Dazodalibep在针对中重度系统性干燥综合征的3期临床试验中，交出了一份令人振奋的答卷。这项研究聚焦于那些饱受病痛折磨的患者群体，而试验数据无疑为这片治疗荒漠带来了希望的甘霖。结果显示，与安慰剂组相比，接受Dazodalibep治疗的患者在关键疗效指标上均实现了统计学意义上的显著改善。分析人士指出，该药物的成功若能在后续环节得以延续，其市场潜力不容小觑，或将重新定义干燥综合征的治疗格局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIB","IE0002141913.USD","IBB","IE00BJJMRZ35.SGD","BBH","LU1057294990.SGD","AMGN","LU1571399168.USD","PBE","IE00BJT1NW94.SGD","LU0109394709.USD","LU2089984988.USD","SG9999001440.SGD","IE00B2B36J28.USD","LU0122379950.USD","LU2242652126.USD","LU2468319806.SGD","TBXU","BK4566","PJP","BK4588","LU0058720904.USD","LU0868494617.USD","LU2242646821.SGD","LU0289739699.SGD","LU1023059063.AUD","LU1983299246.USD","IBBQ","IE0009355771.USD","LU0889565916.HKD","LU0320765992.SGD","LU2112291526.USD","BK4599","BK4581","IE00B4R5TH58.HKD","BK4585","BK4534","LU1061106388.HKD","BK4139","IE00BFTCPJ56.SGD","BK4533"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1196869155","title":"安进：Dazodalibep在系统性疾病活动方面展现出统计学显著且具有临床意义的改善","url":"https://stock-news.laohu8.com/highlight/detail?id=1196869155","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1196869155?lang=zh_cn&edition=full","pubTime":"2026-09-22 21:01","pubTimestamp":1790082073,"startTime":"0","endTime":"0","summary":"安进公司宣布，其实验性药物Dazodalibep在治疗中取得了重大突破。最新研究数据显示，该药物在改善系统性疾病活动方面，不仅达到了统计学上的显著效果，更在临床实践中展现出切实的改善意义。\n这一积极结果无疑为患者群体带来了新的希望，同时也为安进在竞争激烈的医药研发领域增添了重要砝码。相关研究的具体数据与详细分析，预计将在后续的医学会议或学术期刊中进一步披露。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2242646821.SGD","IE0009355771.USD","IE00B2B36J28.USD","LU0058720904.USD","IE00BFTCPJ56.SGD","BBH","LU0109394709.USD","LU0868494617.USD","BK4566","LU1057294990.SGD","LU0122379950.USD","LU0889565916.HKD","BK4599","BK4534","LU2112291526.USD","BK4588","IE0002141913.USD","IE00BJJMRZ35.SGD","PJP","PBE","IBB","SG9999001440.SGD","BK4585","LU1983299246.USD","BK4139","BK4533","TBXU","IBBQ","LU0289739699.SGD","IE00BJT1NW94.SGD","IE00B4R5TH58.HKD","AMGN","LU1571399168.USD","BK4581","LU2468319806.SGD","LU0320765992.SGD","LU1023059063.AUD","BIB","LU2089984988.USD","LU2242652126.USD","LU1061106388.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144298886","title":"安进：Dazodalibep治疗中重度症状性干燥综合征的Oasiz 303三期研究预计2026年第四季度完成","url":"https://stock-news.laohu8.com/highlight/detail?id=1144298886","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1144298886?lang=zh_cn&edition=full","pubTime":"2026-09-22 21:00","pubTimestamp":1790082009,"startTime":"0","endTime":"0","summary":"安进（Amgen）披露，其针对中重度症状性干燥综合征（Sjögren's Disease）所开展的Dazodalibep三期临床研究——即Oasiz 303试验，预计将于2026年第四季度圆满完成。这一时间表的明确，为该公司在自身免疫疾病领域的管线推进提供了新的节点参照。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PBE","LU1061106388.HKD","LU0122379950.USD","IE00BJJMRZ35.SGD","BIB","LU0320765992.SGD","LU2242646821.SGD","LU2242652126.USD","LU0868494617.USD","LU2468319806.SGD","LU1023059063.AUD","AMGN","BBH","LU0109394709.USD","LU2089984988.USD","LU0289739699.SGD","LU1057294990.SGD","BK4566","LU1571399168.USD","PJP","IE00B4R5TH58.HKD","IE0009355771.USD","IE00BFTCPJ56.SGD","SG9999001440.SGD","IE00B2B36J28.USD","BK4585","LU1983299246.USD","BK4599","IBB","BK4533","IE0002141913.USD","BK4139","LU0889565916.HKD","TBXU","LU2112291526.USD","BK4534","BK4588","BK4581","LU0058720904.USD","IE00BJT1NW94.SGD","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1196050236","title":"福泰制药：Inaxaplin在两种AMKD患者队列中均展现良好安全性与耐受性","url":"https://stock-news.laohu8.com/highlight/detail?id=1196050236","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1196050236?lang=zh_cn&edition=full","pubTime":"2026-09-22 20:02","pubTimestamp":1790078535,"startTime":"0","endTime":"0","summary":"福泰制药近日披露，其候选药物Inaxaplin在两项针对APOL1介导肾病的临床试验队列中，表现出令人满意的安全性和耐受性特征。业内观察人士指出，Inaxaplin若能在后续研究中持续印证其价值，有望为AMKD这一难治性疾病带来突破性治疗选择。福泰制药此番公告，不仅回应了市场对管线进展的关切，也再次凸显了其在精准医疗赛道上的深耕意图。随着更多数据的积累，Inaxaplin的临床定位将愈发清晰，其对患者生活质量的实际改善程度也将接受更严苛的检验。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0009355771.USD","IE00B2B36J28.USD","LU0058720904.USD","LU1069344957.HKD","IE00BFTCPJ56.SGD","BBH","LU0109394709.USD","LU0234570918.USD","SG9999001176.USD","LU2362540622.SGD","IE0002270589.USD","LU0061475181.USD","SGXZ57979304.SGD","LU0823416689.USD","LU0889565916.HKD","LU2237438978.USD","IE00BZ9MQY76.HKD","LU0417517546.SGD","LU2324357040.USD","LU2362541513.USD","SG9999013999.USD","LU2362541273.HKD","BK4588","TBXU","IE0002141913.USD","LU2456880835.USD","IE00BJJMRZ35.SGD","LU0079474960.USD","LU2417539215.USD","PBE","IBB","BK4585","VRTX","IE00B19Z3B42.SGD","BK4139","BK4533","IE00B19Z9Z06.USD","IBBQ","LU0289739699.SGD","LU1093756325.SGD","LU1674673691.USD","LU2236285917.USD","LU2462157665.USD","IE00B894F039.SGD","LU1035775433.USD","IDNA","BK4532","IE00BJT1NW94.SGD","IE00B4R5TH58.HKD","LU1585245621.USD","LU0256863811.USD","IE00B19Z9P08.USD","LU0432979614.USD","LU1778281490.HKD","LU1430594728.SGD","LU2468319806.SGD","BK4567","GNMX","LU0320765992.SGD","BIB","LU2089984988.USD","SG9999001176.SGD","IE00B19Z3581.USD","LU1674673428.USD","LU1093756168.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160767959","title":"福泰制药公布Inaxaplin针对APOL1介导肾病（AMKD）其他人群的2B期AMPLIFIED研究积极结果，并完成2/3期AMPLITUDE试验入组","url":"https://stock-news.laohu8.com/highlight/detail?id=1160767959","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1160767959?lang=zh_cn&edition=full","pubTime":"2026-09-22 20:01","pubTimestamp":1790078494,"startTime":"0","endTime":"0","summary":"福泰制药今日宣布，其候选药物Inaxaplin在针对APOL1介导肾病其他患者群体的2B期AMPLIFIED研究中，取得了令人鼓舞的积极数据。与此同时，公司还确认，备受瞩目的2/3期AMPLITUDE注册试验已顺利达成全部患者入组目标。目前，该疾病在全球范围内缺乏针对性治疗手段，Inaxaplin有望为患者带来突破性的治疗选择。业内分析人士认为，AMPLIFIED研究的积极结果以及AMPLITUDE试验的顺利入组，进一步巩固了福泰制药在肾脏病精准医疗领域的领先地位。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GNMX","BK4588","BIB","LU2468319806.SGD","LU1674673691.USD","LU0823416689.USD","LU2362541273.HKD","LU0061475181.USD","VRTX","LU1069344957.HKD","TBXU","LU0320765992.SGD","LU0234570918.USD","LU2089984988.USD","SG9999013999.USD","IE00B19Z9P08.USD","LU1093756168.USD","LU1430594728.SGD","BK4139","IE00BFTCPJ56.SGD","SGXZ57979304.SGD","BK4567","LU2456880835.USD","LU2236285917.USD","LU0058720904.USD","BK4585","BK4532","LU1585245621.USD","BBH","LU0079474960.USD","LU0889565916.HKD","IBBQ","IE00B4R5TH58.HKD","LU2324357040.USD","LU1674673428.USD","LU2362540622.SGD","IE00BJT1NW94.SGD","IE00B19Z9Z06.USD","LU0417517546.SGD","SG9999001176.USD","LU0256863811.USD","IE0002270589.USD","LU0432979614.USD","IE00BJJMRZ35.SGD","LU0109394709.USD","LU2462157665.USD","IE00B19Z3581.USD","PBE","IE00B2B36J28.USD","BK4533","IBB","IE0002141913.USD","IE00B894F039.SGD","LU0289739699.SGD","IE00B19Z3B42.SGD","LU1093756325.SGD","IE00BZ9MQY76.HKD","LU1778281490.HKD","LU2417539215.USD","LU2237438978.USD","SG9999001176.SGD","LU1035775433.USD","IE0009355771.USD","LU2362541513.USD","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191181268","title":"福泰制药：Inaxaplin显著降低UACR达42.7%——针对适度蛋白尿APKD患者展现积极疗效","url":"https://stock-news.laohu8.com/highlight/detail?id=1191181268","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1191181268?lang=zh_cn&edition=full","pubTime":"2026-09-22 20:01","pubTimestamp":1790078474,"startTime":"0","endTime":"0","summary":"生物制药巨头福泰制药近日披露了一项令人瞩目的临床数据：其候选药物Inaxaplin在治疗伴有适度蛋白尿的常染色体显性多囊肾病患者中，于第13周时使尿白蛋白肌酐比较基线大幅下降42.7%。值得关注的是，这项数据凸显了Inaxaplin在降低蛋白尿方面的显著潜力，而蛋白尿正是衡量肾脏损伤程度及预测疾病进展风险的关键生物标志物。尽管现有数据展现出鼓舞人心的信号，但业界普遍认为，要全面评估Inaxaplin的长期获益与安全性，尚需更大规模、更长周期的临床验证。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2324357040.USD","BK4588","LU0417517546.SGD","BK4139","IE00B2B36J28.USD","IE00B19Z3581.USD","IE00B4R5TH58.HKD","SG9999001176.SGD","LU2362541513.USD","LU1093756325.SGD","IE00B19Z9P08.USD","LU0109394709.USD","LU1674673428.USD","BIB","LU0823416689.USD","VRTX","GNMX","IE0002270589.USD","BK4585","LU2089984988.USD","IE00BJT1NW94.SGD","IE00B894F039.SGD","TBXU","LU1778281490.HKD","LU2417539215.USD","LU0320765992.SGD","BK4533","IE0009355771.USD","LU1430594728.SGD","LU1585245621.USD","IE00B19Z3B42.SGD","LU0889565916.HKD","LU0432979614.USD","LU2362541273.HKD","IBB","LU0079474960.USD","IE0002141913.USD","LU2456880835.USD","IE00BFTCPJ56.SGD","LU2468319806.SGD","BBH","SG9999001176.USD","LU0061475181.USD","IE00B19Z9Z06.USD","LU0289739699.SGD","LU2462157665.USD","LU2362540622.SGD","SG9999013999.USD","LU1035775433.USD","BK4567","LU0058720904.USD","LU0256863811.USD","BK4532","LU1069344957.HKD","LU1093756168.USD","LU1674673691.USD","LU2237438978.USD","LU2236285917.USD","IBBQ","PBE","IE00BJJMRZ35.SGD","LU0234570918.USD","IDNA","SGXZ57979304.SGD","IE00BZ9MQY76.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669169682","title":"公告精选︱科达制造：拟投资约45亿元建设年产50万吨石墨负极材料一体化项目；百花医药：不涉及创新药研发","url":"https://stock-news.laohu8.com/highlight/detail?id=2669169682","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669169682?lang=zh_cn&edition=full","pubTime":"2026-09-21 21:52","pubTimestamp":1789998737,"startTime":"0","endTime":"0","summary":"逸豪新材：拟定增募资不超过18亿元用于增资收购铭丰电子不低于78%股权","market":"sg","thumbnail":"https://img7.gelonghui.com/column/2/111.png?guru_height=540&guru_width=375","type":0,"news_type":0,"thumbnails":["https://img7.gelonghui.com/column/2/111.png?guru_height=540&guru_width=375"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/6758003","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["IBB","PBE","BK0155","WRND","XLVI","BK0102","SETM","APXH","600499","600721","BIOY","BBP","BK4585","SBIO","LFSC","BK0216","GSKH","BK0251","BK4588","BK0188","GDOC","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147475205","title":"福泰制药获Leerink Partners恢复覆盖，给予跑赢大盘评级及594美元目标价","url":"https://stock-news.laohu8.com/highlight/detail?id=1147475205","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1147475205?lang=zh_cn&edition=full","pubTime":"2026-09-21 18:04","pubTimestamp":1789985058,"startTime":"0","endTime":"0","summary":"Leerink Partners近日宣布恢复对福泰制药的覆盖研究，并给予该股\"跑赢大盘\"评级。这家华尔街投行同时将目标价设定为594美元，彰显其对福泰制药未来走势的乐观预期。这一动作引发市场广泛关注——毕竟，Leerink Partners在生物医药领域的分析素以严谨著称。其恢复覆盖并给出积极评级，无疑为投资者注入了一针强心剂。值得注意的是，这一评级决定恰逢生物科技板块整体回暖之际。多重因素交织下，福泰制药的股价表现或将迎来新的催化剂。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0009355771.USD","IE00B2B36J28.USD","LU0058720904.USD","LU1069344957.HKD","IE00BFTCPJ56.SGD","BBH","LU0109394709.USD","LU0234570918.USD","SG9999001176.USD","LU2362540622.SGD","IE0002270589.USD","LU0061475181.USD","SGXZ57979304.SGD","LU0823416689.USD","LU0889565916.HKD","LU2237438978.USD","IE00BZ9MQY76.HKD","LU0417517546.SGD","LU2324357040.USD","LU2362541513.USD","SG9999013999.USD","LU2362541273.HKD","BK4588","TBXU","IE0002141913.USD","LU2456880835.USD","IE00BJJMRZ35.SGD","LU0079474960.USD","LU2417539215.USD","PBE","IBB","BK4585","VRTX","IE00B19Z3B42.SGD","BK4139","BK4533","IE00B19Z9Z06.USD","IBBQ","LU0289739699.SGD","LU1093756325.SGD","LU1674673691.USD","LU2236285917.USD","LU2462157665.USD","IE00B894F039.SGD","LU1035775433.USD","IDNA","BK4532","IE00BJT1NW94.SGD","IE00B4R5TH58.HKD","LU1585245621.USD","LU0256863811.USD","IE00B19Z9P08.USD","LU0432979614.USD","LU1778281490.HKD","LU1430594728.SGD","LU2468319806.SGD","BK4567","GNMX","LU0320765992.SGD","BIB","LU2089984988.USD","SG9999001176.SGD","IE00B19Z3581.USD","LU1674673428.USD","LU1093756168.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669137049","title":"创新药热度飙升，关注100%创新药研发标的","url":"https://stock-news.laohu8.com/highlight/detail?id=2669137049","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669137049?lang=zh_cn&edition=full","pubTime":"2026-09-21 13:55","pubTimestamp":1789970100,"startTime":"0","endTime":"0","summary":"MACD金叉信号形成，这些股涨势不错！","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-09-21/doc-inisqkzy8876594.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["MEDX","BBP","XLVI","WRND","GSKH","BIOY","IBBQ","GDOC","06978","BK1161","LNGR","BK4585","159992","SBIO","IBB","APXH","LFSC","BK4588","BK1574","PBE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668916276","title":"专利到期潮撞上研发断档，生物类似药“空窗”逼近！美国医疗体系恐少省1890亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2668916276","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668916276?lang=zh_cn&edition=full","pubTime":"2026-09-18 09:45","pubTimestamp":1789695928,"startTime":"0","endTime":"0","summary":"美国因此面临着一个巨大的“生物类似药空窗”，这可能导致1890亿美元的医疗成本节约空间流失。据AAM统计，去年仿制药与生物类似药合计为美国节约医疗开支4960亿美元，较2024年增加300亿美元;其中仿制药贡献了95%的节约额。AAM表示，生物类似药的研发主要瞄准市场潜力大、专利即将到期的生物药。那些专利到期前年销售额超10亿美元的原研药，对应的生物类似药竞争尤为激烈。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1497739.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2272731782.SGD","XPH","LU2473716301.USD","BK4588","IBB","IE00B5TLWC47.USD","LU2272731600.USD","LU1992135399.USD","LU2322448791.USD","PPH","159891","LU2272731865.HKD","BK4585","LU2322448957.HKD","LU1992135472.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668162209","title":"专利到期潮撞上研发断档，生物类似药“空窗”逼近！美国医疗体系恐少省1890亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2668162209","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668162209?lang=zh_cn&edition=full","pubTime":"2026-09-18 09:45","pubTimestamp":1789695928,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4585","LU2272731865.HKD","BK4588","IBB","LU1992135472.HKD","LU2322448957.HKD","XPH","LU2322448791.USD","LU2473716301.USD","LU1992135399.USD","IE00B5TLWC47.USD","LU2272731600.USD","LU2272731782.SGD","PPH"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":-0.0157},{"period":"1month","weight":-0.0231},{"period":"3month","weight":0.0524},{"period":"6month","weight":0.2156},{"period":"1year","weight":0.3868},{"period":"ytd","weight":0.2204}],"compareEarnings":[{"period":"1week","weight":-0.0042},{"period":"1month","weight":0.0029},{"period":"3month","weight":0.0258},{"period":"6month","weight":0.1649},{"period":"1year","weight":0.1429},{"period":"ytd","weight":0.1204}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"安硕纳斯达克生物科技ETF追踪纳斯达克生物医疗指数(Biotechnology Index)。Biotechnology Index包含的标的为在纳斯达克上市的生物医疗公司。\n风险提示：标的成分和权重，有可能随着时间的迁移而发生变化。","yearOnYearQuotes":[{"month":1,"riseRate":0.722222,"avgChangeRate":0.019108},{"month":2,"riseRate":0.611111,"avgChangeRate":-0.001245},{"month":3,"riseRate":0.555556,"avgChangeRate":0.002788},{"month":4,"riseRate":0.5,"avgChangeRate":0.003638},{"month":5,"riseRate":0.611111,"avgChangeRate":0.009102},{"month":6,"riseRate":0.777778,"avgChangeRate":0.027534},{"month":7,"riseRate":0.722222,"avgChangeRate":0.03565},{"month":8,"riseRate":0.5,"avgChangeRate":0.006092},{"month":9,"riseRate":0.444444,"avgChangeRate":-0.000493},{"month":10,"riseRate":0.368421,"avgChangeRate":-0.014939},{"month":11,"riseRate":0.833333,"avgChangeRate":0.040881},{"month":12,"riseRate":0.555556,"avgChangeRate":0.007272}],"exchange":"NASDAQ","name":"生物科技指数ETF-iShares Nasdaq","nameEN":"iShares Biotechnology ETF"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"生物科技指数ETF-iShares Nasdaq(IBB)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供生物科技指数ETF-iShares Nasdaq(IBB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"生物科技指数ETF-iShares Nasdaq,IBB,生物科技指数ETF-iShares Nasdaq股票,生物科技指数ETF-iShares Nasdaq股票老虎,生物科技指数ETF-iShares Nasdaq股票老虎国际,生物科技指数ETF-iShares Nasdaq行情,生物科技指数ETF-iShares Nasdaq股票行情,生物科技指数ETF-iShares Nasdaq股价,生物科技指数ETF-iShares Nasdaq股市,生物科技指数ETF-iShares Nasdaq股票价格,生物科技指数ETF-iShares Nasdaq股票交易,生物科技指数ETF-iShares Nasdaq股票购买,生物科技指数ETF-iShares Nasdaq股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"生物科技指数ETF-iShares Nasdaq(IBB)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供生物科技指数ETF-iShares Nasdaq(IBB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}